Innovation in Action

Advancing the Pipeline

Baxter's R&D pipeline focuses on products and therapies that have the potential to satisfy unmet clinical needs, expand patient access to vital treatments, advance standards of care and patient convenience, improve medical treatment, and reduce medication errors. The company plans to continue to grow R&D spending, with an increasing percentage of investment in exploratory and early-stage initiatives. The company also plans to continue to pursue business development initiatives, collaborations and alliances as part of its long-term growth strategy. Several regulatory approvals and product launches, as well as the initiation of a number of Phase III clinical trials, mark the company’s progress.

Recent Highlights

In 2009, Baxter increased its spending on R&D to $917 million - the highest level in the company's history and an 11 percent increase from 2008. The company plans to continue to grow R&D spending, with an increasing percentage of investment in exploratory and early-stage initiatives. Baxter advanced 13 Phase III clinical trials and numerous early-stage programs that have the potential to profoundly impact the treatment and delivery of care for chronic diseases like Alzheimer's disease, hemophilia, end-stage renal disease, immune deficiencies, as well as public health threats like pandemic and seasonal influenza.

2009 activities included:

  • Initiated a Phase III clinical trial evaluating the use of ARTISS [Fibrin Sealant (Human)] in facial surgery in the United States.
  • Completed Phase III confirmatory study of Baxter's Vero cell-derived seasonal influenza vaccine in healthy adults, and Baxter's Vero cell culture-based prepandemic (VEPACEL) influenza vaccine is in Phase III clinical trials.
  • Completed enrollment in the first Phase III clinical trial on a subcutaneous delivery of GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] (IGIV) in patients with Primary Immune Deficiency.
  • Expanded the patient enrollment in a Phase III clinical trial evaluating the use of GAMMAGARD LIQUID therapy for treatment of mild-to-moderate Alzheimer's disease.
  • Received marketing authorization from the European Commission for CELVAPAN H1N1, the company's Vero cell culture-based pandemic influenza vaccine.
  • Launched OLIMEL, the company's latest triple-chamber container system for parenteral nutrition in certain European markets.
  • Launched HYLENEX recombinant (hyaluronidase human injection) in October 2009, coinciding with the publication of data from Baxter's first HYLENEX recombinant clinical trial in the medical journal Pediatrics.
  • Continued research on combining Baxter's TISSEEL fibrin sealant with complementary technology to potentially regenerate skin and bone.
  • Continued development of a home hemodialysis platform to provide another option for patients seeking home dialysis for end-stage renal disease.
  • Begun work in pediatric rehydration with the INFUSE PEDS-2 trial, which is a head-to-head comparison of subcutaneous rehydration versus IV rehydration in dehydrated children.
  • Conducted two clinical studies testing the effectiveness of Baxter's V-Link Luer-Activated Device with VitalShield Protective Coating on patients.